Costs associated with treating cancers such as MDS are increasing as new medicines are developed and combination regimens gain hold. This trend presents an important challenge to MCOs who must respond to changing protocols and rising costs. Whereas the new oncology medications offer a unique opportunity to improve outcomes in patients with MDS, they also demand high financial outlay, which in turn necessitates adjustments in benefits programs.
Anaemia is prevalent in patients with
In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most
Allogeneic stem cell transplantation (SCT) is the only therapeutic modality at present that may be delivered with curative intent in
The pathogenesis of
Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months.
The wide spectrum of clonal hematopoietic disorders that fall under the
Myelodysplastic syndrome (MDS) is composed of a diverse spectrum of hematopoietic stem cell malignancies characterized by ineffective blood